Publications by authors named "R Mican"
Background: Studies on switching to tenofovir alafenamide (TAF)-based regimens raise concerns about a worse metabolic profile in people with HIV, even though most received tenofovir disoproxil fumarate (TDF) in their previous regimen. This study aims to evaluate changes in lipid fractions, glucose, and serum markers for hepatic steatosis (HS) after switching from a TDF- or TAF-sparing regimen to bictegravir/emtricitabine/TAF (B/F/TAF).
Methods: We performed a retrospective cohort study of people with HIV who switched to B/F/TAF from TDF- or TAF-sparing regimens between January 2019 and May 2022 with at least 6 months of follow-up.
Article Synopsis
- DTG + RPV is a recommended HIV treatment for those already stable on therapy, and this study compares its effectiveness and tolerability between women and men.
- Over 48 weeks, the study analyzed outcomes for 307 HIV patients (71 women, 236 men) who switched to the DTG + RPV regimen, focusing on viral load levels and side effects.
- Findings showed men had slightly better viral load suppression than women and reported fewer side effects leading to discontinuation of therapy, with weight gain reported for both genders.
Background: Switching strategy with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) has become a gold standard for people living with HIV (PLWH), achieving high efficacy and safety rates. However, data regarding immune status in long-term real-life cohorts of pretreated patients are needed.
Methods: We performed a multicentre, non-controlled, retrospective study in virologically suppressed PLWH switching to B/F/TAF.
Patterns of Sexualized Drug Use among Gay, Bisexual, and Other Men Who Have Sex with Men Living with HIV: Insights from a Comprehensive Study-The U-SEX-2 GESIDA 9416 Study.
J Clin Med
November 2023
Background: Sexualized drug use (SDU) has become a public health concern in recent years. This study aimed to estimate the prevalence of SDU in gay, bisexual, and other men who have sex with men living with HIV (HIV + GBMSM) in Madrid during 2019/2020 and compare it with data from 2016/2017 in order to detect changes in patterns.
Methods: We analyzed the frequency of SDU in a sample of HIV + GBMSM attending HIV clinics, who participated in an anonymous online survey regarding sexual behavior and recreational drug use.
Background: Dolutegravir (DTG) plus lamivudine (3TC) has proven highly efficacious as a switching strategy in virologically suppressed people with HIV (PWH). As this strategy was introduced relatively recently, real-world, long-term durability studies are lacking.
Methods: We performed a retrospective review of treatment-experienced patients who started DTG + 3TC in a cohort of PWH.